1MRNA trade ideas
MODERNA (MRNA) BULLISH IN SEVERAL WAYS. I'M GOING LONGModerna has recently broken out of the downtrend line of the past 6 months. It has also formed a cup and handle with a double bottom of support. MRNA closed Friday, Dec. 6th, 2024 above both its' 8 Day EMA and its' 21 Day EMA. RSI is rising and about to cross the centerline. I predict the stock will continue to work its' way back up to the $118 level over the next 6 months, where it will meet significant resistance due to overhead supply.
Thanks
Is Risk in your DNA?I hope to get perspective from others looking at this company. Is this whole sector with pharmacy overlooked? CVS poses as a play in brand? I am no marketing expert.
$MRNA can’t find a bottomThis name has been on my watch the last 6 months. I continued to wait for a possible bottom for a position but every time it pops it just goes down some more. Another delisting here on the $NASDAQ. I expect this to reach newer lows below $36. NASDAQ:SMCI in the same boat. This chart actually looks prime for more downside with these candles. Short it.
WALLSTREETLOSER
$MRNA hasn't been here since APRIL 2020.. pt. 2Posted a quick chart via phone earlier but had to take a look on the desktop. A crucial point here at a supply that once took off 4 years ago.. interesting. Target is $35, leave runners once $36 hits. This could have been a bottom for NASDAQ:MRNA but after the rebalancing of the NASDAQ this may bottom out at $30.
WSL
Retrace Back To Golden Pocket between .5 and .618 Fib.It has broken above the trend line and I believe the stock has bottomed. Even though the price targets have been lowered, it will likely fill the gap in the golden pocket zone. Hence $103 by Feb 2025.
MRNA - long positionhi traders,
Let's have a look at MRNA stock on the weekly time frame.
As we can see, the price is retesting the COVID lows from 2020 which haven't been retested yet.
The RSI is very oversold and we believe that the trend reversal is likely.
Our strategy is to take a long position now around 55$.
Stop loss should be placed below 50$
Our target is at the golden pocket fibonacci which is around 126$.
MRNA earnings 11/7/24MRNA 2 day chart just printed a high probability long signal on the Fib TSI indicator yesterday. My speculation is that seasonally, it's a good idea to go long MRNA heading into the winter cold season. This is a simple trade entry based off the Fib TSI indicator long signal at 53. A round number tight stop at 50. And 106 profit level based off August 1st gap fill area equaling a 2x stock gain. MRNA earnings are on 11/7/24 pre - market.
long = 53
stop = 50
profit = 106
1/17/25 expiry options data:
Put Volume Total 169
Call Volume Total 545
Put/Call Volume Ratio 0.31
Put Open Interest Total 67,001
Call Open Interest Total 76,725
Put/Call Open Interest Ratio 0.87
3/21/25 expiry options data:
Put Volume Total 827
Call Volume Total 93
Put/Call Volume Ratio 8.89
Put Open Interest Total 24,788
Call Open Interest Total 16,059
Put/Call Open Interest Ratio 1.54
Options ideas:
buy 1/17/25 expiry calls
sell 3/21/25 expiry puts
Potential massive reversal for MRNA?🔉Sound on!🔉
Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
MRNA Set up for a Fast Rip to $87Flu season incoming, beginning of October to December
MRNA Set up for a retracement back up to $80-$87
$MRNA * MODERNA TC FIB EWP WEEKLY TF ANALYSISTechnical analysis of Moderna, Inc. (MRNA), using Elliott Wave Principle along with Fibonacci retracement levels. Here’s a breakdown of what I observe and what it might mean:
1. Elliott Wave Count : The chart features a labeled Elliott Wave pattern, with clear impulse waves and corrective waves (A, B, C). We seem to be in the C wave of a larger corrective phase, indicating that the stock is undergoing a downward correction after a prior upward impulse.
2. Fibonacci Retracements : Various Fibonacci retracement levels (0.382, 0.5, 0.618) are drawn on both the upward and downward moves. The chart suggests that the stock has already retraced past significant Fibonacci levels during its correction. The price is nearing the golden pocket retracement level ($48.60 to $43), which should act as a key support level.
3. Trend Channels : There are two visible trend channels: a green upward channel representing the previous bullish trend, and a red downward channel indicating the ongoing bearish phase. The stock appears to have broken out of the upward channel and is firmly within the downward channel, signaling the continuation of a bearish trend.
4. RSI (Relative Strength Index) : The RSI indicator at the bottom of the chart is around 31.34, which is close to the oversold region (typically below 30). This suggests that the stock may be nearing a point of exhaustion in its selling pressure, potentially signaling a reversal.
Overall Interpretation:
• Bearish Momentum: The stock is in a corrective phase, as indicated by the Elliott Wave count and the downward trend channel.
• Key Support Levels: Prices around $48 are critical Fibonacci levels that may offer support.
• Possible Reversal: The RSI suggests that the stock is approaching oversold territory, which could indicate a bounce or reversal soon, but it’s important to monitor how the price reacts at these levels.
MRNA - Moderna, Inc.Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Moderna (MRNA) Stock Plummets on Weak Sales OutlookModerna Inc. (NASDAQ: NASDAQ:MRNA ) is facing tough times as its stock dropped over 11% during Thursday’s premarket trading session. The biotech giant, known for its breakthrough COVID-19 vaccine, released a disappointing sales outlook for the upcoming years, sparking a significant sell-off among investors.
Weak Sales Outlook and Pipeline Adjustments
Moderna (NASDAQ: NASDAQ:MRNA ) has projected sales between $2.5 billion and $3.5 billion for 2025, a far cry from the multi-billion dollar revenues seen during the peak of the COVID-19 pandemic. This forecast falls below analysts’ expectations, who anticipated revenues of $3.27 billion for 2024 and $3.74 billion for 2025.
The company’s revenue has been declining since the pandemic boom, with 2023 expected to be the lowest annual revenue since its first COVID-19 vaccine launch in late 2020. Moderna (NASDAQ: NASDAQ:MRNA ) is now betting on its 10 new product launches by 2027 to drive an average annual growth rate of 25% in revenue between 2026 and 2028. However, Moderna CFO James Mock highlighted the uncertainty of the COVID-19 and RSV markets, admitting that these new products may not contribute significant revenue until later years.
Moderna’s strategic pivot includes significant cost-cutting measures, with plans to slash $1.1 billion in expenses by 2027. This includes reducing R&D spending from an expected $4.8 billion this year to between $3.6 billion and $3.8 billion by 2027. Despite these reductions, the company is still committed to advancing its pipeline, which includes new mRNA vaccines against RSV, norovirus, and cancer, among others.
Challenges Ahead: Competition and Pipeline Delays
Moderna’s market position is increasingly challenged by competitors like Pfizer (PFE) and GSK (GSK), who are also pursuing expanded approvals for their RSV vaccines in the same high-risk adult age groups. Moderna’s recent decision to drop its request for fast-track approval of its standalone flu vaccine reflects its strategic realignment towards combination shots that offer protection against multiple viruses, including COVID-19 and influenza.
The company's standalone flu shot, mRNA-1010, recently met immune-response targets in clinical trials, but it's still a long way from regulatory approval. Moderna's CEO, Stéphane Bancel, remains optimistic about the company's robust drug development capabilities, boasting that Moderna's rate of success from phase one to phase three trials is “six times higher” than the industry average.
Technical Outlook
Technically, Moderna's stock price is reflecting the weak fundamentals. The stock is down 10.45% in premarket trading, which adds to the already bearish momentum. On Wednesday, the Relative Strength Index (RSI) for Moderna (NASDAQ: NASDAQ:MRNA ) was 37, indicating a weakened position. The current dip below the $73 mark will likely push the RSI further into oversold territory, raising concerns about heightened selling pressure.
The critical technical level to watch is the $60 pivot, a major support zone that aligns with the September 2020 lows. Should Moderna’s stock breach this support, it could trigger a cascade of selling as investors lose confidence, potentially leading to a more severe downturn. This level has historically served as a strong base, and a breakdown could erase gains made over the last four years.
What’s Next for Moderna?
While Moderna’s long-term prospects hinge on the successful launch of its new mRNA-based therapies, the immediate outlook appears bleak. The company’s efforts to expand into new markets like RSV and flu vaccines are promising, but the revenue impact of these products won’t be felt until at least 2025. Investors should brace for volatility as the company navigates through a post-pandemic market landscape with reduced COVID-19 vaccine sales and increasing competition.
For now, Moderna's technical indicators signal caution. The stock's proximity to major support zones and the bearish momentum could prompt further declines if market sentiment does not improve. Investors are advised to keep a close eye on how the company’s strategic decisions unfold and whether Moderna (NASDAQ: NASDAQ:MRNA ) can successfully deliver on its ambitious pipeline goals in the face of growing market challenges.
Buy NOW think later!!
1. Moderna is extremely oversold and we’re starting to see a very reliable bottoming pattern; i.e. bullish divergence on the RSI. This exact setup was seen few months back (see chart) and that’s how I called the bottom back then.
2. Given all the news about bird flu, not only does it put a floor underneath this stock but makes it quite likely a major rally initiates VERY SOON.
3. I think MRNA is in a major ABC wave. The strong move down past 3-4 months was wave B and a wave C could start soon.
there’s an easy double if one buys at CMP
Moderna Technical PerspectiveFrom a technical perspective, according to Moderna's weekly chart, sentiment is clearly to the downside in the long term. Following a test of support-turned-resistance at US$87.35, follow-through selling has emerged over the past few weeks. This has led price action within a stone’s throw of support consisting of US$74.46 and a trendline resistance-turned-support line, extended from the high of US$497.49. Should price dip through this area, this could lay the groundwork for a test of the October 2023 lows at US$62.55.
From the H4 timeframe, price dipped through support at US$77.41 and has retested the underside of the level heading into the close of trading last week. Assuming this base holds ground, a test of the horizontal weekly support level at US$74.46 is likely, with follow-through selling towards support on the H4 timeframe at US$71.72 also a possibility. Consequently, this could open short-term selling opportunities for traders in the short term. Further selling is possible if the unit clears bids around the weekly/H4 support combination between US$71.72 and US$74.46.
MRNA, bound for exponential growth! MASSIVE RISE in 12 months!MRNA went parabolic during the COVID era reaching as high as 500. Then it went on a cooling down mode coincindingly when the pandemic has started fading.
Now a BIG SHIFT has been registered based on its long term data metrics. This is massive because it took the stock 2.5 years to make this happen again.
A breakout has been spotted on its long term trend. We got a break in structure confirming that major position takers has started piling up already for that new round of massive growth prospect.
Histogram registered it's elusive 'hop' over the line already. First time in ages. The most awaited confirmation is ON.
Best seeding season is NOW.
This will be an investors' gem.
Spotted at 140.0
Interim target at 300.0
Long term: 500.
TAYOR.
$MRNA set for a bullish run as WHO announces monkey pox threat.#YUSUKE_ALERT 💉 NASDAQ:MRNA
Potential bullish reversal at support level PT3 ($81.95)
Watch for break above PT1 ($91.68) for upside momentum
Current price: $84.93
Stop loss: Below PT3
Target: PT2 ($102.9) or PT3 ($122.45)
Time frame: Short to medium-term
Moderna (MRNA) - Bullish Call Action
#YUSUKE_ALERT 💉 NASDAQ:MRNA 08/23/24 $92C
ASK: 90 @ $0.86 ($8K)
Vol/OI: 1K/85 (13.84)
Time: 08/15/2024 @ 11:03:34am
Moderna's daily chart shows a potential bullish reversal at the PT3 support level ($81.95). The high volume-to-open interest ratio on this call option suggests traders are positioning for a possible upward move. Key levels to watch:
Current price: $84.93
Resistance: PT1 ($91.68)
Targets: PT2 ($102.9), PT3 ($122.45)
AST SpaceMobile (ASTS) - Heavy Put Volume
Multiple alerts for ASTS puts came through, with extraordinarily high Vol/OI ratios:
$29P Aug 16, 24 (1d)
ASK: 120 @ $0.95 ($11K)
Vol/OI Ratio: 773.50
$30P Aug 16, 24 (1d)
ASK: 100 @ $1.00 ($10K)
Vol/OI Ratio: 328.80
$28P Aug 16, 24 (1d)
ASK: 100 @ $0.74 ($7K)
Vol/OI Ratio: Infinity (no previous open interest)
This concentrated put buying could indicate bearish sentiment or a hedge against a long position.
Other Notable Alerts
Nike (NKE): FWB:81P Aug 30, 24 (15d) with a Vol/OI ratio of 11.34
Affirm (AFRM): $27.5P Aug 23, 24 (8d) with infinite Vol/OI ratio
Sea Limited (SE): Multiple $79P Aug 16, 24 (1d) orders with high Vol/OI ratios
What This Means for Traders
MRNA: Watch for a break above $91.68 as a potential entry for bullish positions.
ASTS: The heavy put volume suggests caution. Consider hedging long positions or exploring bearish strategies.
1. WMT $72 P 08/23/2024
Alert Time: 10:50am 08/15
Volume: 7,672
Open Interest: 134
Volume/OI Ratio: 57.25
Price: $0.42
Total Premium: $386K
%OTM: 1.82%
Execution Time: 08/15 @ 10:49am
2. NKE $80 P 08/16/2024
Alert Time: 10:03am 08/15
Volume: 2,080
Open Interest: 208
Volume/OI Ratio: 10.00
Price: $0.09
Total Premium: FWB:42K
%OTM: 2.30%
Execution Time: 08/15 @ 10:03am
3. PINS $32 C 08/23/2024
Alert Time: 09:44am 08/15
Volume: 11,220
Open Interest: 371
Volume/OI Ratio: 30.24
Price: $0.24
Total Premium: $239K
%OTM: 3.41%
Execution Time: 08/15 @ 09:44am
4. RUN $20.5 C 08/23/2024
Alert Time: 09:07am 08/15
Volume: 7,290
Open Interest: 102
Volume/OI Ratio: 71.47
Price: $0.34
Total Premium: $214K
%OTM: 7.05%
Execution Time: 08/15 @ 09:07am
5. CHWY $26 P 08/16/2024
Alert Time: 09:02am 08/15
Volume: 1,859
Open Interest: 72
Volume/OI Ratio: 25.82
Price: $0.17
Total Premium: $10K
%OTM: 1.29%
Execution Time: 08/15 @ 09:02am
Ask: 59.71%, Bid: 36.69%, Mid: 3.60%
6. W $46 C 08/23/2024
Alert Time: 08:57am 08/15
Volume: 461
Open Interest: 291
Volume/OI Ratio: 1.58
Price: $0.80
Total Premium: $35K
%OTM: 4.91%
Execution Time: 08/15 @ 08:57am
Ask: 95.01%, Bid: -2.17%, Mid: 2.82%
7. RUN $20.5 C 08/23/2024
Alert Time: 08:23am 08/15
Volume: 1,753
Open Interest: 102
Volume/OI Ratio: 17.19
Price: $0.31
Total Premium: $53K
%OTM: 7.39%
Execution Time: 08/15 @ 08:23am
These alerts are primarily focused on options with high volume relative to open interest, indicating unusual trading activity. The alerts cover various stocks including WMT, NKE, PINS, RUN, CHWY, and W, with a mix of call and put options at different strike prices and expiration dates.
NKE, AFRM, SE: These alerts indicate potential volatility. Research recent news and upcoming events that might be driving this options activity.
Remember, unusual options activity can provide insights, but it's crucial to conduct your own due diligence before making any trading decisions. Disclaimer: This analysis is based on market data as of 08/15/2024 and is for informational purposes only. Always consult with a licensed financial advisor before making investment decisions.
This is a good shortBearish flag forming and the price is hitting the top resistance. Good entry point, great risk-reward. SL triggers if a daily candle closes above the resistance at 90 or so. But it has to close.
MRNA: My first LoveMRNA is poised for a comeback. This is the first stock i ever bought and invested in, its one of the reasons why i started trading, and im glad to introduce it back into my investment portfolio.
Healthcare is recession proof, it can act as a great hedge against big tech, it can be used for diversification, it can benefit as we start a rotation transition, the company has a lot of potential outside COVID with its mRNA technology, and the technicals just look great!
First target 40% upside to 170$ before EOY.
Good luck!
Moderna Stock Dips More Than 20% Amid Slashed Sales GuidanceModerna Inc. (NASDAQ: NASDAQ:MRNA ) experienced a significant drop in its stock price, plummeting over 20%, following the announcement of reduced full-year sales guidance. The biotech company, renowned for its mRNA technology, reported second-quarter earnings that exceeded Wall Street expectations but highlighted several challenges that led to the downward revision of its revenue forecast.
Q2 Performance Overview
Moderna ( NASDAQ:MRNA ) reported a narrower-than-expected loss of $3.33 per share, compared to analyst expectations of a $3.39 loss. The company's revenue for the second quarter stood at $241 million, surpassing the anticipated $132 million. However, this figure still represents a 30% year-over-year decline from the $344 million reported in the same period last year. The decrease was primarily driven by a 37% drop in product sales from its Covid-19 vaccine, Spikevax, which brought in $184 million during the quarter.
Slashed Full-Year Guidance
Despite the better-than-expected quarterly performance, Moderna ( NASDAQ:MRNA ) reduced its 2024 product revenue guidance to a range of $3 billion to $3.5 billion, down from the previous forecast of $4 billion. The company attributed this adjustment to several factors:
1. Lower Sales in Europe: Moderna cited reduced demand for its Covid-19 vaccine in Europe as a major contributor to the lowered guidance.
2. Competitive U.S. Market: The company faces stiff competition in the U.S. market for respiratory vaccines, particularly for its newly approved respiratory syncytial virus (RSV) vaccine, mRESVIA. This vaccine, which targets older adults, entered a market already dominated by Pfizer and GSK.
3. Deferred International Revenue: Moderna indicated the potential for delayed international revenue, pushing some sales into 2025 due to ongoing budget constraints and economic pressures in various countries, including those exacerbated by the war in Ukraine.
Strategic Adjustments and Future Outlook
In response to these challenges, Moderna ( NASDAQ:MRNA ) has been proactive in reducing operating costs. The company's cost of sales for Q2 was $115 million, down 84% from the same period last year. This reduction includes $14 million in write-downs of unused Covid-19 vaccine doses and $55 million in charges related to scaling back its manufacturing footprint.
CEO Stéphane Bancel emphasized the company's commitment to managing costs and optimizing its product pipeline. He noted, “We’ve been having quite intense discussions with governments across Europe to secure Covid vaccine supply contracts, but tight budgets and existing agreements with other suppliers have limited our opportunities.”
Despite the current setbacks, Moderna remains optimistic about its future. The company expects to return to sales growth in 2025 and aims to break even by 2026. Key to this strategy is the launch of new products and continued innovation within its pipeline. Moderna currently has 45 products in development, with five in late-stage trials. These include a combination shot targeting Covid-19 and the flu, which could receive approval as early as 2025, a stand-alone flu vaccine, and a personalized cancer vaccine in collaboration with Merck.
Investor Sentiment and Market Response
While Moderna's shares have risen nearly 20% this year due to increasing confidence in its pipeline and mRNA platform, the recent guidance cut has significantly impacted investor sentiment.
Modern stock ( NASDAQ:MRNA ) has dropped from its consolidation zone and has formed a significant downward gap. In trading, gapping happens when the price of a security jumps to a new price that's not right next to the previous price, creating a gap on the price chart. This can occur during a trading day or when the markets are closed. Gaps can happen unexpectedly when the perceived value of an investment changes due to fundamental or technical factors, such as earnings. In this case, NASDAQ:MRNA is in a downward gap, also known as a negative gap, which occurs when the opening price of a stock on the second day is lower than the closing price on the first day.
Conclusion
Moderna's recent financial performance highlights the volatility and competitive nature of the biotech industry, particularly in the evolving landscape of respiratory vaccines. While the company faces immediate challenges, its strategic cost management and robust pipeline position it for potential recovery and growth in the coming years.
Moderna confluenceNASDAQ:MRNA confluence of MSs horizontal support and diagonal support, with multiple bounces in history...
tight R:R
I'm going to look for an entry to go long here
Bullish Anti-Shark Harmonic on MRNAI've spotted some bullish harmonic patterns on Moderna (MRNA) that are showing strong potential! 📈 There's one fully formed pattern and another one waiting to complete. 📊 The Relative Volume (RVOL) average is backing the strong support levels, suggesting that MRNA might be bottoming out around this area. 🌟
📉 Chart Analysis:
1️⃣ The current pattern shows a potential reversal from the recent downtrend, with significant support around the $104.91 level.
2️⃣ The RVOL indicates increased buying interest, which further supports the likelihood of a bullish move. 📈
🎯 Trade Setup:
Entry Point: Look for confirmations around the support level.
Target 1: $136 💰
Stop Loss: $104.91 🚨
📝 Why I'm Interested:
The combination of harmonic patterns and strong RVOL support makes this setup particularly compelling. Harmonics often signal high probability reversals, and the volume support adds another layer of confidence. 📊📉
📅 Timeframe: I'm looking at this setup on a 3H chart, which means it could take a couple of days to fully play out. ⏳
🔔 Stay Updated: Make sure to keep an eye on the price action and adjust your strategy as needed. Happy trading! 🎯
#MRNA #Harmonics #RVOL #Trading #StockMarket #TechnicalAnalysis #TradeTalkFarsi 📈🚀
